Pierre Raboisson

3.9k total citations
60 papers, 1.8k citations indexed

About

Pierre Raboisson is a scholar working on Molecular Biology, Hepatology and Infectious Diseases. According to data from OpenAlex, Pierre Raboisson has authored 60 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 22 papers in Hepatology and 18 papers in Infectious Diseases. Recurrent topics in Pierre Raboisson's work include Hepatitis C virus research (22 papers), Hepatitis B Virus Studies (13 papers) and HIV/AIDS drug development and treatment (13 papers). Pierre Raboisson is often cited by papers focused on Hepatitis C virus research (22 papers), Hepatitis B Virus Studies (13 papers) and HIV/AIDS drug development and treatment (13 papers). Pierre Raboisson collaborates with scholars based in Belgium, United States and France. Pierre Raboisson's co-authors include Maxwell D. Cummings, Oliver Lenz, Kenneth Simmen, Herman de Kock, Tse‐I Lin, Bertil Samuelsson, Åsa Rosenquist, Christian Gachet, Jean‐Pierre Cazenave and Anthony Baurand and has published in prestigious journals such as Angewandte Chemie International Edition, PLoS ONE and Hepatology.

In The Last Decade

Pierre Raboisson

58 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pierre Raboisson Belgium 24 636 634 555 534 497 60 1.8k
T.C. Appleby United States 22 305 0.5× 775 1.2× 276 0.5× 272 0.5× 361 0.7× 29 1.5k
Robert B. Perni United States 23 868 1.4× 609 1.0× 506 0.9× 988 1.9× 424 0.9× 49 2.4k
Wonsuk Chang United States 17 567 0.9× 571 0.9× 435 0.8× 458 0.9× 671 1.4× 28 1.6k
Vincent Lévêque United States 28 803 1.3× 549 0.9× 219 0.4× 643 1.2× 659 1.3× 41 1.7k
Stefania Di Marco Italy 22 275 0.4× 1.8k 2.9× 309 0.6× 330 0.6× 249 0.5× 32 2.6k
Mark W. Stahlhut United States 21 472 0.7× 600 0.9× 264 0.5× 390 0.7× 656 1.3× 45 1.7k
Ted Fox United States 18 449 0.7× 1.3k 2.0× 122 0.2× 435 0.8× 198 0.4× 24 2.0k
Bruce S. Ross United States 17 551 0.9× 762 1.2× 351 0.6× 452 0.8× 644 1.3× 42 1.6k
Congrong Niu United States 18 1.1k 1.8× 674 1.1× 179 0.3× 1.2k 2.2× 842 1.7× 29 2.1k
Mirko Brunetti Italy 16 543 0.9× 874 1.4× 240 0.4× 303 0.6× 222 0.4× 20 1.5k

Countries citing papers authored by Pierre Raboisson

Since Specialization
Citations

This map shows the geographic impact of Pierre Raboisson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Raboisson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Raboisson more than expected).

Fields of papers citing papers by Pierre Raboisson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Raboisson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Raboisson. The network helps show where Pierre Raboisson may publish in the future.

Co-authorship network of co-authors of Pierre Raboisson

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre Raboisson. A scholar is included among the top collaborators of Pierre Raboisson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre Raboisson. Pierre Raboisson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vanrusselt, Hannah, Dieudonné Buh Kum, Valério Taverniti, et al.. (2023). Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles. Journal of Virology. 97(10). e0072223–e0072223. 4 indexed citations
2.
Liu, Cheng, Sandro Boland, Michael D. Scholle, et al.. (2021). Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development. Antiviral Research. 187. 105020–105020. 39 indexed citations
3.
Zhang, Qingling, Sandrine Vendeville, V. N. Serebryany, et al.. (2020). ALG-000184, a prodrug of capsid assembly modulator ALG-001075, demonstrates best-in-class preclinical characteristics for the treatment of chronic hepatitis B. Journal of Hepatology. 73. S880–S881. 4 indexed citations
4.
5.
Gurard‐Levin, Zachary A., Liu C, Andreas Jekle, et al.. (2020). Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry. Antiviral Research. 182. 104924–104924. 26 indexed citations
6.
Luong, Xuan G., Sarah Stevens, Andreas Jekle, et al.. (2020). Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH). PLoS ONE. 15(12). e0240338–e0240338. 31 indexed citations
7.
Geluykens, Peggy, Olivia Goethals, Stefaan Last, et al.. (2017). Characterization of a dengue NS4B inhibitor originating from an HCV small molecule library. Antiviral Research. 147. 149–158. 15 indexed citations
8.
McGowan, David C., Alex De Groot, Frederik Pauwels, et al.. (2017). Synthesis and evaluation of novel HCV replication inhibitors. Molecular Diversity. 21(2). 475–481. 2 indexed citations
9.
Cummings, Maxwell D., Jimmy Lindberg, Tse‐I Lin, et al.. (2010). Innentitelbild: Induced‐Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target (Angew. Chem. 9/2010). Angewandte Chemie. 122(9). 1552–1552. 1 indexed citations
10.
Lin, Tse‐I, Oliver Lenz, Gregory Fanning, et al.. (2009). In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor. Antimicrobial Agents and Chemotherapy. 53(4). 1377–1385. 142 indexed citations
11.
Raboisson, Pierre, Tse‐I Lin, Herman de Kock, et al.. (2008). Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(18). 5095–5100. 18 indexed citations
12.
Raboisson, Pierre, Oliver Lenz, Tse‐I Lin, et al.. (2007). Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(7). 1843–1849. 11 indexed citations
13.
Joseph, Benoı̂t, Florence Popowycz, Philippe Bernard, & Pierre Raboisson. (2007). Synthesis of 8-Substituted Pyrazolo[1,5-a]-1,3,5-triazine Derivatives by Palladium-Catalyzed Cross-Coupling Reactions. Synthesis. 2007(3). 367–374. 2 indexed citations
14.
Raboisson, Pierre, Christian D. Muller, Jean‐Marie Reimund, et al.. (2007). Cyclic nucleotide phosphodiesterase type 4 inhibitors: Evaluation of pyrazolo[1,5-a]-1,3,5-triazine ring system as an adenine bioisostere. European Journal of Medicinal Chemistry. 43(4). 816–829. 30 indexed citations
15.
Raboisson, Pierre, Renée L. DesJarlais, Jennifer Lattanze, et al.. (2006). Identification of novel short chain 4-substituted indoles as potent αvβ3 antagonist using structure-based drug design. European Journal of Medicinal Chemistry. 42(3). 334–343. 18 indexed citations
16.
Parks, Daniel J., Louis V. LaFrance, Raul R. Calvo, et al.. (2006). Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein–protein interaction through structure-based drug design. Bioorganic & Medicinal Chemistry Letters. 16(12). 3310–3314. 57 indexed citations
17.
Raboisson, Pierre, Carl L. Manthey, Margery A. Chaikin, et al.. (2006). Novel potent and selective αvβ3/αvβ5 integrin dual antagonists with reduced binding affinity for human serum albumin. European Journal of Medicinal Chemistry. 41(7). 847–861. 10 indexed citations
18.
Leonard, Kristi, Juan Marugán, Pierre Raboisson, et al.. (2006). Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity. Bioorganic & Medicinal Chemistry Letters. 16(13). 3463–3468. 49 indexed citations
19.
Raboisson, Pierre, Claire Lugnier, Christian D. Muller, et al.. (2003). Design, synthesis and structure–activity relationships of a series of 9-substituted adenine derivatives as selective phosphodiesterase type-4 inhibitors. European Journal of Medicinal Chemistry. 38(2). 199–214. 34 indexed citations
20.
Baurand, Anthony, Pierre Raboisson, Monique Freund, et al.. (2001). Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. European Journal of Pharmacology. 412(3). 213–221. 128 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T.C. Appleby Breakdown of academic impact, for papers by Robert B. Perni Breakdown of academic impact, for papers by Wonsuk Chang Breakdown of academic impact, for papers by Vincent Lévêque Breakdown of academic impact, for papers by Stefania Di Marco Breakdown of academic impact, for papers by Mark W. Stahlhut Breakdown of academic impact, for papers by Ted Fox Breakdown of academic impact, for papers by Bruce S. Ross Breakdown of academic impact, for papers by Congrong Niu Breakdown of academic impact, for papers by Mirko Brunetti
Rankless by CCL
2026